Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial
ABSTRACT Background Lung cancer is a leading cause of cancer‐related deaths. Perioperative therapies, including neoadjuvant chemo‐immunotherapy, have improved outcomes, but combining them with antiangiogenic drugs may offer further benefits. This study evaluated the 3‐year efficacy and safety of neo...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2025-08-01
|
| Seri Bilgileri: | Thoracic Cancer |
| Konular: | |
| Online Erişim: | https://doi.org/10.1111/1759-7714.70149 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|